Mapp Biopharmaceutical & Gilead Sciences
3 shared events · Importance 3 · Last updated Jul 10, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Mapp Biopharmaceutical is collaborating with Gilead Sciences on clinical trials to evaluate experimental treatments for the Bundibugyo Ebola outbreak.
Tech
Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, one of the experimental treatments prioritized by the World Health Organization for the Bundibugyo strain of Ebola.
Gilead Sciences: Gilead Sciences developed the antiviral remdesivir and experimental oral antiviral obeldesivir, both prioritized by the World Health Organization for treatment and prevention of the Bundibugyo strain of Ebola.
May 28, 2026 · 6 articles
Accidents
Mapp Biopharmaceutical: Supplying experimental MBP134 antibody for trials; potential positive impact if treatment proves effective.
Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.
Mar 09, 2018 · 314 articles
Accidents
Mapp Biopharmaceutical: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.
Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.
May 18, 2026 · 505 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Mapp Biopharmaceutical and Gilead Sciences interact across events, view sentiment trends, and discover connected entities.
Open Dashboard